Do adjuvant aromatase inhibitors increase the cardiovascular risk in postmenopausal women with early breast cancer? Meta-analysis of randomized trials.
about
Cardiovascular riskAmerican Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer.Care of the cancer survivor: metabolic syndrome after hormone-modifying therapy.Comorbidities and cardiovascular disease risk in older breast cancer survivorsRisk of myocardial infarction, stroke, and fracture in a cohort of community-based breast cancer patients.A randomized, double-blind, controlled study of exemestane versus anastrozole for the first-line treatment of postmenopausal Japanese women with hormone-receptor-positive advanced breast cancer.Exemestane in the adjuvant treatment of breast cancer in postmenopausal women.Early breast cancer in the older woman.Cardiotoxicity of molecularly targeted agentsLipid profiles within the SABRE trial of anastrozole with and without risedronate.Cardiotoxicity of aromatase inhibitors and tamoxifen in postmenopausal women with breast cancer: a systematic review and meta-analysis of randomized controlled trials.Systemic cancer therapy: achievements and challenges that lie aheadCancer therapy-induced cardiac toxicity in early breast cancer: addressing the unresolved issues.Breast cancer survivorship symptom management: current perspective and future development.Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative GroupAdjuvant treatment of breast cancer in postmenopausal women: role of exemestane.Aromatase inhibitors in the treatment of breast cancer in post-menopausal female patients: an update.Early recurrence risk: aromatase inhibitors versus tamoxifen.Aromatase inhibitor therapy: toxicities and management strategies in the treatment of postmenopausal women with hormone-sensitive early breast cancer.Putting the cardiovascular safety of aromatase inhibitors in patients with early breast cancer into perspective: a systematic review of the literature.Cardiovascular sequelae of radiation therapy.Building a cardio-oncology program in a small- to medium-sized, nonprimary cancer center, academic hospital in the USA: challenges and pitfalls.The use of concurrent hormonotherapy and radiotherapy does not deteriorate radiation-induced cardiac toxicity.Benefit/risk for adjuvant breast cancer therapy with tamoxifen or aromatase inhibitor use by age, and race/ethnicity.Metabolic Syndrome in Korean Cancer Survivors and Family Members: A Study in a Health Promotion Center.Cardiovascular disease and mortality after breast cancer in postmenopausal women: Results from the Women's Health Initiative.Patient and physician perceptions on continuing aromatase inhibitors beyond the 5-year mark.Adjuvant aromatase inhibitor options in overweight and obese postmenopausal women with breast cancer.The clinical impact of a cardiologic follow-up in breast cancer survivors: an observational study.Cancer and Thrombotic Risk: The Platelet Paradigm.Letrozole: advancing hormone therapy in breast cancer.Current Status of Extended Adjuvant Endocrine Therapy in Early Stage Breast Cancer.The Relative Benefits of Tamoxifen in Older Women with T1 Early-Stage Breast Cancer Treated with Breast-Conserving Surgery and Radiation TherapyLong term adjuvant endocrine therapy and risk of cardiovascular disease in female breast cancer survivors: systematic review
P2860
Q26825634-69565AF0-4CB3-45A7-B948-083BF883B11BQ33631047-E0D19847-B73F-4864-B780-E8A05E4BA766Q33649441-14CE65A6-AC88-4C53-9DA4-7763B9C12F27Q33810528-752054E3-4488-4773-B5F1-09738E0A526DQ34007066-BFD69265-97ED-4FA4-AC54-BED535A01CB5Q34347274-F8062950-D20E-42B9-BB3A-AE3A78C6E95AQ35440357-1456E475-719A-413D-BB57-9D62EE0973E2Q35584539-421A8697-CB78-4B82-BF70-CA4BE11A13BCQ35878459-4DC78A82-7333-4535-BB30-9B78812579B2Q36161292-5C97C2BB-118A-4175-B150-D52BD3DE0347Q36229869-2673D42E-107B-4FFF-83DB-239A9B827438Q36821958-C42DA879-BD6F-48BE-A361-9ECD19B75DF3Q36887091-1F65B9A0-92FE-4381-80DC-3217FF585C89Q36956837-A1F28CF6-4C7F-463B-B370-E5063399ECACQ37119390-257D90C3-BD8D-40BC-A91B-5FD5DC59DA9CQ37355561-DCF62867-8550-4774-84E8-EE72469B388AQ37355574-94ACAEB3-E970-4D15-8F11-3754A0A15340Q37782092-9B6C0796-97EC-4848-97BD-9295AA277FF5Q37830371-30BCDAE6-E543-4144-BBFC-93B92BDFFD31Q37955223-DDF7C90C-B40F-4D84-B595-105A226B9408Q38209876-3F4A6F5F-16F6-4B8B-89F9-61AF99757BAEQ38978112-A473DB3D-51B8-42AC-B9FD-2429BD51BB03Q39421580-CA437D2A-81E8-41ED-A5B9-D21E498364AEQ40280431-BAE3397D-2AFC-49AD-BA1E-3FF40E454744Q41442945-A32C8E04-1DF4-4296-9C1B-075DD2FB8821Q42362046-B1630483-3E9E-4168-977B-C6103190130DQ43627047-6186DCDC-D320-4A0B-93A6-22846AA761C0Q43924246-12958FA8-CEF5-4EE9-AD2F-A8FB90FC5F49Q43958676-C6905B5C-BA32-4D37-921E-E9681DFA4A87Q44264785-568BC21F-B277-411D-A126-B18FB3096160Q48348546-50AE2704-EB94-47FF-AF11-C5114D2FED21Q54987182-AA9EA17B-42CB-4B4F-B1E7-8DAEEF5F7669Q55001238-BAD8B5BE-BC45-4FE8-8B02-E8D399BEBA0CQ57293528-968FE6A9-7E18-4004-A961-E7D783D7CD40
P2860
Do adjuvant aromatase inhibitors increase the cardiovascular risk in postmenopausal women with early breast cancer? Meta-analysis of randomized trials.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Do adjuvant aromatase inhibito ...... analysis of randomized trials.
@en
Do adjuvant aromatase inhibito ...... analysis of randomized trials.
@nl
type
label
Do adjuvant aromatase inhibito ...... analysis of randomized trials.
@en
Do adjuvant aromatase inhibito ...... analysis of randomized trials.
@nl
prefLabel
Do adjuvant aromatase inhibito ...... analysis of randomized trials.
@en
Do adjuvant aromatase inhibito ...... analysis of randomized trials.
@nl
P2093
P2860
P50
P356
P1433
P1476
Do adjuvant aromatase inhibito ...... analysis of randomized trials.
@en
P2093
Cecilia Nisticò
Edmondo Terzoli
Federica Cuppone
Francesco Cognetti
Michele Milella
Paolo Carlini
Sonal Gandhi
Sunil Verma
P2860
P304
P356
10.1002/CNCR.23171
P407
P577
2008-01-01T00:00:00Z